QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ampoule contains 10mg/ml apomorphine hydrochloride
Treatment of motor fluctuations (“on-off” phenomena) in patients with Parkinson's disease which are not sufficiently controlled by personally titrated oral anti-Parkinson medication.
- Type I glass ampoules containing 2ml Solution for Injection or Infusion, in packs of 5 ampoules (total dose: 20mg/ 2ml).
- Type I glass ampoules containing 5ml Solution for Injection or Infusion, in packs of 5 ampoules (total dose: 50mg/ 5ml)
APO-go Ampoules 10 mg/ml Solution for Injection or Infusion is for subcutaneous use by intermittent bolus injection. APO-go Ampoules 10 mg/ml Solution for Injection or Infusion may also be administered as a continuous subcutaneous infusion by minipump and/or syringe-driver. 1mg of apomorphine HCl (0.1ml), that is approximately 15-20 micrograms/kg, may be injected subcutaneously during a hypokinetic or 'off' period and the patient is observed over 30 minutes for a motor response. If no response, or an inadequate response, is obtained a second dose of 2 mg of apomorphine HCl (0.2ml) is injected subcutaneously and the patient observed for an adequate response for a further 30 minutes. The dosage may be increased by incremental injections with at least a forty minute interval between succeeding injections, until a satisfactory motor response is obtained. The daily dose of APO-go varies widely between patients, typically within the range of 3-30 mg, given as 1-10 injections and sometimes as many as 12 separate injections per day. It is recommended that the total daily dose of apomorphine HCl should not exceed 100 mg and that individual bolus injections should not exceed 10 mg.
MARKETING AUTHORIZATION HOLDER